Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 21 min ago
Peer-reviewedCC BY-NC 4.0Journal of Korean Medical Science

Previously Unrecognized Distinct Laryngeal Lesions During Lazertinib Therapy in EGFR-Mutated NSCLC: A Case Series

  • Seung Heon Kang1,2
  • Hyojin Kim3
  • Jeong-Yeon Ji4
  • Woo-Jin Jeong4
4 affiliations
  1. 1Department of Otorhinolaryngology-Head and Neck Surgery, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea .
  2. 2Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea .
  3. 3Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea .
  4. 4Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea .
Read full textDOICite

Abstract

Lazertinib (LECLAZA®) is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC), especially in patients with brain metastases. While common adverse events such as rash and pruritus have been reported, voice-related complications and structural laryngeal lesions have not previously been reported. Here, we describe four NSCLC patients who developed new-onset voice changes or globus sensation during lazertinib-based therapy. Laryngoscopic examination revealed multifocal, broad-based polypoid mucosal thickening that was atypical for benign conditions such as contact granuloma or reflux-related disease. Histopathology in one patient demonstrated benign inflamed granulation tissue, and all lesions remained stable without interval progression over 15–36 months of follow-up. Given the small number of cases and the potential confounders, a causal association with lazertinib cannot be established. However, awareness of these benign-appearing mucosal findings may help clinicians avoid unnecessary biopsy or interruption of cancer treatment when evaluating throat or voice symptoms in patients receiving lazertinib therapy.

Related

  1. 249 A genome-scale, in vivo transcription factor screen identifies a previously unrecognized factor that enhances CAR-T persistence and tumor control under high-dose rechallenge
    Yuan Liu, Hao Wang, Qi Zhang +10
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  2. Previously Unrecognized Congenital Hypogonadotropic Hypogonadism in an 89-Year-Old Man: A Case Report.
    Mafalda Ferreira, Patrícia O Saraiva, Franciso Nunes +2
    CureusPeer-reviewedCC BYFull textObstetrics, gynaecology & paediatricsEurope PMC
  3. Massive enlargement of a previously unrecognized bronchogenic cyst over 8 years with intracystic hemorrhage and complex surgical resection: a case report.
    Shuhei Kobayashi, Eriko Fukui, Hideki Nagata +5
    General thoracic and cardiovascular surgery casesPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMC
  4. Development of the OncoScore: A Diagnostic Prediction Score for Previously Unrecognized Malignancy in Patients with Acute Pulmonary Embolism
    Aleksandra Kozic, Sonja Salinger, Boris Dzudovic +14
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  5. Prevalence of ECG-detected and previously unrecognized atrial fibrillation among older adults attending a family health center: a single-center cross-sectional screening study
    Nilüfer Aktura, Bekir Aktura, Fatih Erkam Olgun
    BMC Primary CarePeer-reviewedCC BYFull textCardiovascular medicineDOAJ

Cite

BibTeXRIS
BibTeX
@article{kang2026previously,
  title = {{Previously Unrecognized Distinct Laryngeal Lesions During Lazertinib Therapy in EGFR-Mutated NSCLC: A Case Series}},
  author = {Seung Heon Kang and Hyojin Kim and Jeong-Yeon Ji and Woo-Jin Jeong},
  journal = {Journal of Korean Medical Science},
  year = {2026},
  month = oct,
  doi = {10.3346/jkms.2026.41.e340},
  url = {https://doi.org/10.3346/jkms.2026.41.e340},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Previously Unrecognized Distinct Laryngeal Lesions During Lazertinib Therapy in EGFR-Mutated NSCLC: A Case Series
AU  - Seung Heon Kang
AU  - Hyojin Kim
AU  - Jeong-Yeon Ji
AU  - Woo-Jin Jeong
PY  - 2026
DA  - 2026/10/14
JO  - Journal of Korean Medical Science
DO  - 10.3346/jkms.2026.41.e340
UR  - https://doi.org/10.3346/jkms.2026.41.e340
AB  - Lazertinib (LECLAZA®) is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC), especially in patients with brain metastases. While common adverse events such as rash and pruritus have been reported, voice-related complications and structural laryngeal lesions have not previously been reported. Here, we describe four NSCLC patients who developed new-onset voice changes or globus sensation during lazertinib-based therapy. Laryngoscopic examination revealed multifocal, broad-based polypoid mucosal thickening that was atypical for benign conditions such as contact granuloma or reflux-related disease. Histopathology in one patient demonstrated benign inflamed granulation tissue, and all lesions remained stable without interval progression over 15–36 months of follow-up. Given the small number of cases and the potential confounders, a causal association with lazertinib cannot be established. However, awareness of these benign-appearing mucosal findings may help clinicians avoid unnecessary biopsy or interruption of cancer treatment when evaluating throat or voice symptoms in patients receiving lazertinib therapy.
SN  - 1011-8934
SN  - 1598-6357
ER  -